Streetbeat News

Analyst Ratings

VTLE

Citigroup analyst Paul Diamond has initiated coverage on Vital Energy (NYSE:VTLE) with a Buy rating and set a price target of $60.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:32 pm

NKTR

JP Morgan analyst Jessica Fye has reinstated coverage on Nektar Therapeutics (NASDAQ:NKTR) with an Underweight rating.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:29 pm

FL

KSS

LEG

Analysts have provided ratings for three high-yield dividend stocks in the consumer discretionary sector: Kohl's Corporation (KSS), Leggett & Platt, Incorporated (LEG), and Foot Locker, Inc. (FL). These stocks offer dividend yields above 7% and have been recently rated by some of Wall Street's most accurate analysts. KSS beat revenue expectations in Q2 FY23, LEG posted downbeat earnings for Q3, and FL is expected to report Q3 results on Nov. 29, 2023.

Portfolio Pulse from Lisa Levin

November 20, 2023 | 1:29 pm

EBS

JP Morgan analyst Jessica Fye has reinstated Emergent BioSolutions (NYSE:EBS) with an Underweight rating.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:28 pm

ESPR

JP Morgan analyst Jessica Fye has reinstated coverage on Esperion Therapeutics (NASDAQ:ESPR) with a Neutral rating.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:26 pm

AMRN

JP Morgan analyst Jessica Fye has reinstated coverage on Amarin Corp (NASDAQ:AMRN) with an Underweight rating.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:21 pm

DCPH

JP Morgan analyst Jessica Fye has reinstated coverage on Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Neutral rating and set a price target of $14.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:17 pm

BCRX

JP Morgan analyst Jessica Fye has reinstated BioCryst Pharma (NASDAQ:BCRX) with an Overweight rating and set a price target of $10.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:15 pm

MIRM

JP Morgan analyst Jessica Fye has reinstated Mirum Pharmaceuticals (NASDAQ:MIRM) with an Overweight rating and set a price target of $37.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:14 pm

CRNX

JP Morgan analyst Jessica Fye has reinstated Crinetics Pharmaceuticals (NASDAQ:CRNX) with an Overweight rating and set a price target of $35.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:12 pm